Literature DB >> 19492969

Mycobacterium tuberculosis: drug resistance and future perspectives.

Giovanna Riccardi1, Maria Rosalia Pasca, Silvia Buroni.   

Abstract

TB is still a global health problem. The selection and spread of multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis strains represents a threat for global TB control. The reappearance of TB has driven an increased interest in understanding the mechanisms of drug action and drug resistance, which could provide a significant contribution in the development of new antimicrobials. In this article, the authors describe the mode of action and the resistance mechanisms of the principal first- and second-line antitubercular agents, namely isoniazid, ethionamide, ethambutol, D-cycloserine, rifamycins, fluoroquinolones, streptomycin, linezolid and pyrazinamide. A brief outline of the seven drugs in clinical development is reported, showing how the development of new TB drugs is still required.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19492969     DOI: 10.2217/fmb.09.20

Source DB:  PubMed          Journal:  Future Microbiol        ISSN: 1746-0913            Impact factor:   3.165


  25 in total

Review 1.  Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.

Authors:  Barbara A Brown-Elliott; Kevin A Nash; Richard J Wallace
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

2.  Lantibiotics as prospective antimycobacterial agents.

Authors:  John Donaghy
Journal:  Bioeng Bugs       Date:  2010 Nov-Dec

Review 3.  Nervous system effects of antituberculosis therapy.

Authors:  Joseph S Kass; Wayne X Shandera
Journal:  CNS Drugs       Date:  2010-08       Impact factor: 5.749

4.  Application of genotype MTBDRplus in rapid detection of the Mycobacterium tuberculosis complex as well as its resistance to isoniazid and rifampin in a high volume laboratory in Southern China.

Authors:  Lei Zhang; Yuanxing Ye; Lina Duo; Tingting Wang; Xingbo Song; Xiaojun Lu; Binwu Ying; Lanlan Wang
Journal:  Mol Biol Rep       Date:  2010-09-18       Impact factor: 2.316

5.  Clinical isolates of Mycobacterium tuberculosis in four European hospitals are uniformly susceptible to benzothiazinones.

Authors:  Maria Rosalia Pasca; Giulia Degiacomi; Ana Luisa de Jesus Lopes Ribeiro; Francesca Zara; Patrizia De Mori; Beate Heym; Maurizio Mirrione; Roberto Brerra; Laura Pagani; Leopoldo Pucillo; Panajota Troupioti; Vadim Makarov; Stewart T Cole; Giovanna Riccardi
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

6.  Characterization of Escherichia coli D-cycloserine transport and resistant mutants.

Authors:  Gary Baisa; Nicholas J Stabo; Rodney A Welch
Journal:  J Bacteriol       Date:  2013-01-11       Impact factor: 3.490

7.  Interaction of Ethambutol with human organic cation transporters of the SLC22 family indicates potential for drug-drug interactions during antituberculosis therapy.

Authors:  Xiaolei Pan; Li Wang; Dirk Gründemann; Douglas H Sweet
Journal:  Antimicrob Agents Chemother       Date:  2013-08-05       Impact factor: 5.191

8.  Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China.

Authors:  Zhijian Zhang; Jie Lu; Yufeng Wang; Yu Pang; Yanlin Zhao
Journal:  Antimicrob Agents Chemother       Date:  2013-10-28       Impact factor: 5.191

9.  MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212.

Authors:  Valentina La Rosa; Giovanna Poce; Julio Ortiz Canseco; Silvia Buroni; Maria Rosalia Pasca; Mariangela Biava; Ravikiran M Raju; Giulio Cesare Porretta; Salvatore Alfonso; Claudio Battilocchio; Babak Javid; Flavia Sorrentino; Thomas R Ioerger; James C Sacchettini; Fabrizio Manetti; Maurizio Botta; Alessandro De Logu; Eric J Rubin; Edda De Rossi
Journal:  Antimicrob Agents Chemother       Date:  2011-10-24       Impact factor: 5.191

10.  Structural and biochemical characterization of Mycobacterium tuberculosis CYP142: evidence for multiple cholesterol 27-hydroxylase activities in a human pathogen.

Authors:  Max D Driscoll; Kirsty J McLean; Colin Levy; Natalia Mast; Irina A Pikuleva; Pierre Lafite; Stephen E J Rigby; David Leys; Andrew W Munro
Journal:  J Biol Chem       Date:  2010-09-30       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.